2009 STEDESA (eslicarbazepine acetate) Abstracts
1. Versavel M, Czapinski P, Halasz P, Elger C, Maia J, Almeida L, Soares-da-Silva P. An evaluation of the efficacy and safety of eslicarbazepine acetate (ESL) as add-on treatment in adults with refractory partial-onset seizures: BIA-2093 study. Neurology 2009;72(11, Suppl 3):A352 (Abstract)
2. Versavel M, Halasz P, Elger C, Guekht AB, Maia J, Almeida L, Soares-da-Silva P. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): results of a one-year open-label extension to study BIA-2093-301. Neurology 2009;72(11, Suppl 3):A351 (Abstract)
3. Versavel M, French J, Elger C, Halasz P, Ben-Menachem E, Gabbai AA, Lopes-Lima J, Gil-Nagel A, Maia J, Almeida L, Soares-da-Silva P. An evaluation of the efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with partial-onset seizures: Results from a pooled analysis of three double-blind phase III clinical trials. Presented as a platform presentation at Antiepileptic Drug Trials X, April 15 - 17, 2009 in Coral Gables, FL (Abstract)
4. Czapinski P, Halasz P, Elger C, Maia J, Versavel M, Almeida L, Soares-da-Silva P. An evaluation of the efficacy and safety of eslicarbazepine acetate (ESL) as add-on treatment in adults with refractory partial onset seizures: BIA-2093-301. Presented as a poster presentation at American Society for Experimental NeuroTherapeutics, March 5 - 7, 2009 in Arlington, VA. (Abstract)
5. Halasz P, Elger C, Guekht A, Maia J, Versavel M, Almeida L, Soares-da-Silva P. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): Results of a one-year open-label extension to BIA-2093-301. Presented as a poster presentation at American Society for Experimental NeuroTherapeutics, March 5 - 7, 2009 in Arlington, VA. (Abstract)
6. Versavel M, French J, Elger C, Halasz P, Ben-Menachem E, Gabbai AA, Lopes-Lima J, Gil-Nagel A, Maia J, Almeida L, Soares-da-Silva P. An evaluation of the efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with partial-onset seizures: Results from a pooled analysis of three double-blind phase III clinical trials. Presented as a platform presentation at American Society for Experimental NeuroTherapeutics, March 5 - 7, 2009 in Arlington, VA. (Abstract)
2008 STEDESA (eslicarbazepine acetate) Abstracts
1. Almeida L, Nunes T, Vaz-da-Silva M, Santos AT, Rocha JF, Falcao A, Soares-da-Silva P. Effect of eslicarbazepine acetate on the metformin pharmacokinetics in healthy subjects. Epilepsia 2008;49(Suppl 7):423 (Abstract)
2. Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate (ESL) as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 study. Epilepsia 2008;49(Suppl 7):424 (Abstract)
3. Cramer J, Elger C, Halasz P, Hodoba D, Czlonkowska A, Maia J, Almeida L, Soares-da-Silva P. Improvement in quality-of-life and depressive symptoms during long-term treatment with eslicarbazepine acetate: BIA-2093-301 study. Epilepsia 2008;49(Suppl 7):426 (Abstract)
4. Czapinski P, Halasz P, Elger c, Maia J, Almeida L, Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate (ESL) as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-301 study. Epilepsia 2008;49(Suppl 7):428 (Abstract)
5. Elger C, French J, Halasz P, Ben-Menachem E, Gabbai AA, Lopes-Lima J, Gil-Nagel A, Maia J, Almeida L, Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with partial-onset seizures; Pooled analysis of three double-blind phase KKK clinical studies. Epilepsia 2008;49(Suppl 7):428 (Abstract)
6. Falcao A, Fuseau E, Fabre MA, Maia J, Almeida L, Soares-da-Silva P. Population pharmacokinetics of AEDs after co-administration with eslicarbazepine acetate in adult patients with refractory partial epilepsy. Epilepsia 2008;49(Suppl 7):430 (Abstract)
7. Fuseau E, Fabre MA, Falcao A, Maia J, Almeida L, Soares-da-Silva P. Population pharmacokinetics of eslicarbazepine acetate in adult patients with refractory partial seizures. Epilepsia 2008;49(Suppl 7):432 (Abstract)
8. Gabbai AA, B en-Menachem E, Maia J, Almeida L, Soares-da-Silva P. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): Results of a one-year open-label extension of study BIA-2093-302. Epilepsia 2008;49(Suppl 7):432 (Abstract)
9. Gil-Nagel A, Lopes-Lima J, Maia J, Almeida L, Soares-ooda-Silva P. Efficacy and safety of eslicarbazepine acetate (ESL) as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-303 study. Epilepsia 2008;49(Suppl 7):433 (Abstract)
10. Halasz P, Elger C, Guekht A, Maia J, Almeida L, Soares-da-Silva P. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): Results of a one-year open-label extension to study BIA-2093-301. Epilepsia 2008;49(Suppl 7):435 (Abstract)
11. Lopes-Lima J, Gil-Nagel A, Maia J, Almeida L, Soares-da-Silva P. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): Results of a one-year open-label extension of study BIA-2093-303. Epilepsia 2008;49(Suppl 7):441 (Abstract)
12. Maia J, Almeida L, Fabre MA, Fuseau E, Falcao A, Soares-da-Silva P. Dose-response population analysis of eslicarbazepine acetate in adult patients with refractory partial epilepsy. Epilepsia 2008;49(Suppl 7):443 (Abstract)
13. Pereira H, Lopes-Lima J, Gil-Nagel A, Cramer J, Maia J, Almeida L, Soares-da-Silva P. Improvement in quality-of-life and depressive symptoms during long-term treatment with eslicarbazepine acetate: BIA-2093-303 study. Epilepsia 2008;49(Suppl 7):446 (Abstract)
14. Soares-da-Silva P, Martins-da-Silva A, Gabbai AA, Ben-Menachem E, Cramer J, Maia J, Almeida L. Improvement in quality-of-life and depressive symptoms during long-term treatment with eslicarbazepine acetate: BIA-2093-302 study. Epilepsia 2008;49(Suppl 7):455 (Abstract)